Blueprint Medicines anticipates approximately $130M-$140M in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40M-$50M in collaboration revenues from existing collaborations. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
- Blueprint Medicines: FDA puts partial clinical hold on the Phase 1/2 VELA trial
- Blueprint Medicines to present results from PIONEER trial of AYVAKIT
- Citi opens ‘negative Catalyst Watch’ on Blueprint Medicines into data
- Blueprint Medicines’ Supplemental NDA for Ayvakit approved by FDA
